RU-2861690-C1 - METHOD FOR INCREASING EFFICIENCY OF FRONTAL INSEMINATION OF COWS

Abstract

FIELD: animal husbandry. SUBSTANCE: synchronising sexual oestrus in cows according to the following scheme: on day 1, a first injection of gonadotropin-releasing hormone "Fertagil" at a dose of 1 ml/head is administered intramuscularly to cows, on day 8, a second injection of prostaglandin F2α "Enzaprost" at a dose of 5 ml/head, on day 10, a third injection of gonadotropin-releasing hormone "Fertagil" at a dose of 1 ml/head, with artificial insemination without oestrus detection on days 10 and 11. During the period of sexual oestrus synchronisation, cows are subcutaneously injected with a nucleopeptide at a dose of 30 ml/head five times at 48-hour intervals. EFFECT: increasing the number of fertilised cows. 1 cl, 3 tbl, 1 ex

Inventors

• Khristianovskii Pavel Igorevich
• Platonov Stanislav Andreevich
• Medetov Erlan Sagitovich
• Aldyiarov Timur Bazhikenovich
• RAKHMATULLIN SHAMIL GAFIULLOVICH

Dates

Publication Date

20260507

Application Date

20251203

Claims (1)

1. A method for increasing the efficiency of cow fertilization by frontal insemination, characterized by the fact that cows undergo estrus synchronization according to the following scheme: on the 1st day, the first injection of the gonatropin-releasing hormone "Fertagil" is administered intramuscularly to cows at a dosage of 1 ml/head, on the 8th day, the second injection of the prostaglandin F2α "Enzaprost" at a dosage of 5 ml/head, on the 10th day, the third injection of the gonadotropin-releasing hormone "Fertagil" at a dosage of 1 ml/head, with artificial insemination without detecting estrus on the 10th and 11th days, while during the period of estrus synchronization, cows are subcutaneously injected with a nucleopeptide at a dosage of 30 ml/head five times at intervals of 48 hours.

Description

FIELD OF TECHNOLOGY TO WHICH THE INVENTION RELATES The invention relates to the field of animal husbandry, in particular reproductive biotechnology, namely to methods aimed at increasing the fertility of cows from frontal insemination after synchronization of estrus, and can be used to increase the yield of calves obtained from artificial insemination. LEVEL OF TECHNOLOGY The reproductive capacity of the breeding stock is the main factor in the efficiency of cattle breeding. Currently, a common problem is the decrease in the fertility of cows due to high milk productivity of animals [1], as well as violations of housing conditions - lack of exercise and insolation, untimely detection of cows in heat, etc. [2, 3]. All this leads to a decrease in the fertility of cows with artificial insemination. In this regard, targeted regulation of reproductive processes is of paramount importance, primarily the synchronization of estrus in cows with subsequent frontal insemination [4]. Synchronization of estrus is a biotechnological technique that allows insemination of cows without choice in estrus, obtaining calvings at favorable times and generally increasing the yield of offspring in the herd [5, 6]. However, existing synchronization schemes have a common drawback - low fertility of cows with frontal insemination (35-45%). In addition, addiction of animals to stimulants develops [7, 8]. Therefore, increasing the fertility of cows through frontal insemination is a highly relevant task. Patent RU 2742189, "Method for Correcting the Reproductive Function of High-Producing Cows" [9], states that cows are injected four times during the dry period with a biogenic preparation obtained from slaughterhouse waste, thereby optimizing the time of placental separation and ensuring the cows' timely onset of heat. A disadvantage of this method is that it must be used only during the pre-partum period. Patent RU 2804945, "Method for Synchronizing the Estrous Cycle of Cows," is known. It is based on the "Presynch" synchronization scheme, with cows additionally receiving three doses of the immunostimulant "Isidivit" and a single dose of the vitamin and microelement supplement "Selemag" [10]. A significant drawback of this method is the complexity of implementing the scheme, requiring intervals of varying hours between injections, which is difficult to achieve under production conditions. The closest analogue to the claimed method is patent RU 2849077 [11], which calls for the use of the feed additive "Abiotonic" from 15 days before conception to 30 days after, as well as the feed additive "Abiopeptid" from 30 days before calving to 30 days of lactation, and injections of the drug "Nitamin" one month before calving. This method requires working with cows that spontaneously come into heat, which reduces the versatility of the method and reduces the possibility of reducing the time to calving. The main difference of the claimed method is the use of the drug in cattle not during spontaneous estrus cycles, but by including it in the hormonal synchronization schemes for cows' estrus cycles. To perform synchronization, the Ovsynch scheme was used, based on the use of the drugs Enzaprost and Fertagil. Enzaprost (dinoprost) is a synthetic functional analogue of prostaglandin F2α with a specific luteolytic effect. It causes lysis of the corpus luteum in females, which then activates ovarian follicle growth and ovulation. The drug stimulates myometrial contractility at any stage of pregnancy and at any degree of cervical dilation. It is classified as a moderately hazardous substance (hazard class 3 according to GOST 12.1.007) and is manufactured by Ceva Sante Animale, 10 avenue de la Ballastiere, 33500 Libourne, France. Fertagil is a hormonal medicinal product containing gonadorelin, identical to the natural gonadotropin-releasing hormone, regulates the secretion of luteinizing (LH) and follicle-stimulating (FSH) hormones of the anterior pituitary gland, stimulates the growth and development of follicles, the synthesis and secretion of estrogens, causes ovulation and controls the function of the corpus luteum. In terms of its impact on the body, Fertagil belongs to low-hazard substances (hazard class 4 according to GOST 12.1.007-76), manufactured by Intervet International B.V., Wim de Körverstraat 35, P.O. Box 31 5830 AA Boxmeer, The Netherlands. Nucleopeptide is a biopreparation made from bovine spleen extract, making it a natural product. It contains peptides, nucleosides, nucleotide bases, and other biologically active compounds at a concentration of at least 1 mg/ml. Nucleopeptide is classified as a low-hazard substance (hazard class 4 according to GOST 12.1.007). The manufacturer is Ecokhimtekh, a Russian company. The technical result of this invention is an increase in the percentage of cows conceived after frontal insemination by using additional medications in the heat synchronization regimen. This result is achieved by additionally admi